"GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF" in Patent Application Approval Process (USPTO 20230330265).
In: Cancer Gene Therapy Week, 2023-11-06, S. 710-710
serialPeriodical
Zugriff:
Keywords: Adeno-Associated Virus; Bioengineering; Biotechnology; Cancer; Cancer Gene Therapy; Capsid; Drugs and Therapies; Gene Therapy; Genetics; Gynecology; Health and Medicine; Nerve Tissue Proteins; Nucleocapsid; Oncology; Patent Application; Pharmaceuticals; Phosphoproteins; Proteins; Synapsins; Therapy; Virions; Virology; Viruses; Women's Health EN Adeno-Associated Virus Bioengineering Biotechnology Cancer Cancer Gene Therapy Capsid Drugs and Therapies Gene Therapy Genetics Gynecology Health and Medicine Nerve Tissue Proteins Nucleocapsid Oncology Patent Application Pharmaceuticals Phosphoproteins Proteins Synapsins Therapy Virions Virology Viruses Women's Health 710 710 1 11/06/23 20231106 NES 231106 2023 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A patent application by the inventors HERZOG, Christopher Dean (Fanwood, NJ, US); KARDA, Rajvinder (Maidenhead, GB); NG, Joanna (London, GB); RICKS, David (New York, NY, US); SACRAMENTO, Chester (New York, NY, US); SCHORGE, Stephanie (London, GB); WADDINGTON, Simon Nicholas (London, GB), filed on July 21, 2021, was made available online on October 19, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The rAAV virion of any one of claims 1, 11-15, or 20, wherein the promoter is a CMV promoter, wherein optionally the CMV promoter comprises a sequence at least 95% identical to SEQ ID NO: 16 or 17. A recombinant adeno-associated virus (rAAV) virion, comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding an eEF1A2 protein or a functional variant thereof, operatively linked to a promoter. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF" in Patent Application Approval Process (USPTO 20230330265).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2023-11-06, S. 710-710 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|